The Division of Rheumatology and Immunology at the Medical University of South Carolina (MUSC), Charleston, was formally established in 1974 by its first division chief, E. Carwile LeRoy, MD. Twenty-one years later, when Richard M. Silver, MD, assumed leadership, the division had acquired international renown for its scleroderma research. Now, having just retired as division…
Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes
An analysis of treat-to-target therapy assessing two ultrasound definitions of remission for patients with early rheumatoid arthritis (RA) has concluded that using ultrasound remission as a target was not associated with better long-term outcomes for RA patients.1 Compared with MRI, ultrasound costs less, is more accessible and offers the ability to scan more joints in…
Jessica Farrell, PharmD, in the Spotlight: Why the ARP Is for Me
It was never in the plan for Jessica Farrell, PharmD, to enter rheumatology. In fact, when she applied for one of two pharmacist positions at Albany College of Pharmacy and Health Sciences in 2008, she made it clear she was only interested in the family practice position. “I was offered an interview for the family…
The 2018 ARHP Merit Awards & ACR Distinguished Fellows
CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…
How to Teach in the Inpatient Setting
CHICAGO—Teaching in the inpatient setting can be a tall task, hindered by a lack of time, an unpredictable environment and a variety of learners encountered at different levels. But a few techniques—based mainly on understanding who your students are and how they prefer to learn—can make a big difference, an expert said at the 2018…
Tips for Navigating Your First Medical Faculty Job
CHICAGO—Throughout medical training, you have guideposts and guardrails all around you: academic advisors, professors in the classroom, preceptors in the clinic during residency. But once you get a job as a medical faculty member, you’re basically on your own. “No one really trains you or teaches you about how you’re supposed to negotiate and navigate…
AFLAR Experts Discuss Highlights, Hurdles in Rheumatology in Africa
CHICAGO—Rheumatology physicians and researchers from Africa said the field’s resources and medical literature on the continent are slowly expanding, but they repeatedly lamented that the millions who suffer from rheumatic diseases there have major obstacles to overcome to access care. Their reviews and assessments—sometimes grim and sometimes hopeful—came in a session that was a joint…
Tips for Using Digital Health Tools
CHICAGO—Approximately 200,000 health apps are available through major app stores. Some offer real benefits, said Brennan Spiegel, MD, MSHS, director of health services research at Cedars-Sinai Health System, Los Angeles, Calif. But most, he told attendees at the 2018 ACR/ARHP Annual Meeting, are “rubbish.” “They do one or two things only—and generally not well,” he…
ACR Leaders Discuss E/M Coding Changes, Step Therapy & More
CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…
Bimekizumab Promising for PsA
CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…
- « Previous Page
- 1
- …
- 254
- 255
- 256
- 257
- 258
- …
- 777
- Next Page »